Egrifta Human Growth Hormone Peptide CAS 218949-48-5 HIV Associated Lipodystroph

Egrifta Human Growth Hormone Peptide CAS 218949-48-5 Tesamorelin for Belly fat

Quick details:
Product Name Tesamorelin,Egrifta
Cas No. 218949-48-5
Molecular Formula C221H366N72O67S
Molecular Weight 5135.9
Purity (HPLC) 98.0%min.
Appearance White Powder
Single Impurity (HPLC) 1.0%max
Amino Acid Composition ±10% of theoretical
Peptide Content (N%): >80.0%(by %N)
Water Content (Karl Fischer) <8.0%
Mass Balance 95.0~105.0%
Grade Pharmaceutical Grade
Mass Balance 95.0~105.0%
Storage Reconstitute in ddH2O. Store at -20° C. Product is stable for at least 2 months.
Packaging 2 mg/vial

Description:
Tesamorelin is a synthetic peptide consisting of all 44 amino acids of hGRF with the addition of a trans-3-Hexenoic acid group.
Tesamorelin (also known as Egrifta) is a synthetic form of growth-hormone-releasing hormone which is used in the treatment of HIV-associated lipodystrophy.
p;tendon fibroblasts in a dose-dependent manner as revealed by transwell filter migration assay. BPC 157 also dose dependently accelerated the spreading of tendon fibroblasts on culture dishes. The F-actin formation as detected by FITC-phalloidin staining was induced in BPC 157-treated fibroblasts. The protein expression and activation of FAK and paxillin were determined by Western blot analysis, and the phosphorylation levels of both FAK and paxillin were dose dependently increased by BPC 157 while the total amounts of protein was unaltered. In conclusion, BPC 157 promotes the ex vivo outgrowth of tendon fibroblasts from tendon explants, cell survival under stress, and the in vitro migration of tendon fibroblasts, which is likely mediated by the activation of the FAK-paxillin pathway.
use:Triptorelin raises testosterone levels by causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) and follicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.

Applications
LH and FSH concentrations in heifers were monitored after intramuscular applications of fertirelin acetate and GnRH products including gonadorelin acetate.
Each heifer was exposed to nine applications of each chemical for 8-16 day cycles. Groups were exposed to buserelin, gonadorelin acetate or fertirelin acetate.
After these applications blood samples were drawn 1-8 hours later to log the responses to these chemicals and the different reactions between them.
After plotting this data it was determined that a plateau could be reached applying fertirelin acetate more quickly than the other chemical bodies.